Masimo Corporation (MASI)
(Delayed Data from NSDQ)
$246.11 USD
-5.09 (-2.03%)
Updated Feb 25, 2021 04:00 PM ET
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 24.41% |
| 2 | Buy | 17.88% |
| 3 | Hold | 9.48% |
| 4 | Sell | 5.03% |
| 5 | Strong Sell | 1.87% |
| S&P | 500 | 10.70% |
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
3-Hold of 5 3
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
| Value Score | A |
|---|---|
| Growth Score | A |
| Momentum Score | A |
| VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
D Value D Growth B Momentum D VGM
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
View All Zacks #1 Ranked Stocks
Zacks News
Masimo (MASI) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Masimo (MASI) continues to gain from its key Product segment, which witnessed solid growth in Q4.
ANGONegative Net Change HOLXNegative Net Change MASINegative Net Change ABTNegative Net Change
medical
4 Medical Products Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Rebound in sales volumes and rise in COVID-19 support products sales make us optimistic about MDT, MASI, XRAY and COO's results.
MDTNegative Net Change XRAYNegative Net Change HOLXNegative Net Change MASINegative Net Change COONegative Net Change BSXPositive Net Change LHNegative Net Change
earnings medical
Is a Surprise Coming for Masimo Corporation (MASI) This Earnings Season?
by Zacks Equity Research
Masimo Corporation (MASI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
MASINegative Net Change
earnings medical
Masimo (MASI) Announces Full Market RollOut of SafetyNet-OPEN
by Zacks Equity Research
Masimo (MASI) SafetyNet-OPEN aids organizations in detecting those who are most vulnerable to COVID-19.
HOLXNegative Net Change MASINegative Net Change ABTNegative Net Change ALGNNegative Net Change
medical
Medtronic's (MDT) Nellcor Favored in Study Over Masimo's Oximetry
by Zacks Equity Research
Latest study favors Medtronic's (MDT) Nellcor Pulse Oximetry for all newborns considered for study, unlike from those newborns with Masimo's oximeter.
MDTNegative Net Change HOLXNegative Net Change MASINegative Net Change IDXXNegative Net Change
medical
Why the Earnings Surprise Streak Could Continue for Masimo (MASI)
by Zacks Equity Research
Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
MASINegative Net Change
earnings earnings-beat earnings-esp earnings-estimates earnings-streak zacks-consensus-estimate
Masimo's (MASI) iSirona to Boost Hospital Automation Platform
by Zacks Equity Research
Masimo's (MASI) iSirona helps in efficient workflow in hospitals by providing continuous connectivity, thereby helping clinicians to improve patient outcomes.
HOLXNegative Net Change MASINegative Net Change DCTHNegative Net Change CMDPositive Net Change
Masimo (MASI) Reports Encouraging 2020 Preliminary Results
by Zacks Equity Research
Per the preliminary announcement, Masimo (MASI) projects 2020 product revenues to improve.
HOLXNegative Net Change MASINegative Net Change PKINegative Net Change IDXXNegative Net Change
Digital Health M&As Gain Precedence in the New Normal
by Debanjana Dey
The booming digital health space has been witnessing significant M&A activities amid the pandemic.
PHGNegative Net Change MASINegative Net Change AMNNegative Net Change TDOCNegative Net Change RCMNegative Net Change
computers finance medical tech-stocks
Masimo's (MASI) Telehealth Solution Helps in COVID-19 Crisis
by Zacks Equity Research
Masimo (MASI) is lending support to Renown Health through Masimo SafetyNet in order to manage the COVID-19 surge.
MCKNegative Net Change MASINegative Net Change MMSINegative Net Change PDCONegative Net Change
medical
Masimo (MASI) Releases Favorable Findings on Pulse Oximetry
by Zacks Equity Research
Researchers on probe discover that the use of Masimo's (MASI) SpHb was related to the lower rate of postoperative transfusion, minimal duration of ICU stay and other better outcomes.
DVANegative Net Change MASINegative Net Change ALGNNegative Net Change TMONegative Net Change
medical
Masimo (MASI) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
Masimo (MASI) continues to gain from key Product segment, which witnessed solid growth in Q3.
MASINegative Net Change QDELNegative Net Change IDXXNegative Net Change PODDPositive Net Change
earnings medical
Masimo (MASI) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 42.86% and 1.13%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
MASINegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
ABIOMED (ABMD) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
The full commercial launch of Impella 5.5 in May is expected to have contributed to ABIOMED's (ABMD) fiscal second-quarter results
CAHNegative Net Change MASINegative Net Change ABMDNegative Net Change IDXXNegative Net Change
medical
Quidel (QDEL) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Quidel (QDEL) is likely to have witnessed an uptick in rapid immunoassay revenues in Q3.
CAHNegative Net Change MASINegative Net Change QDELNegative Net Change IDXXNegative Net Change
medical
DaVita (DVA) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Solid performance by the net dialysis and related lab patient service segment is likely to have contributed to DaVita's (DVA) top line in the third quarter.
DVANegative Net Change CAHNegative Net Change MASINegative Net Change IDXXNegative Net Change
medical
Varian (VAR) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Varian's (VAR) solid Oncology platform is expected to have driven fiscal fourth-quarter performance.
CAHNegative Net Change MASINegative Net Change VARNegative Net Change IDXXNegative Net Change
Cerner (CERN) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Cerner's (CERN) third-quarter results are likely to reflect solid show by Subscriptions and Managed Services segments.
SYKNegative Net Change CERNNegative Net Change MASINegative Net Change PACBNegative Net Change
PerkinElmer (PKI) to Post Q3 Earnings: What's in the Offing?
by Zacks Equity Research
PerkinElmer's (PKI) third-quarter results are likely to reflect strong performance at Diagnostics segment.
SYKNegative Net Change MASINegative Net Change PKINegative Net Change PACBNegative Net Change
DexCom (DXCM) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) third-quarter results are likely to reflect rising global awareness of its real-time CGM.
SYKNegative Net Change MASINegative Net Change DXCMNegative Net Change PACBNegative Net Change
earnings medical
Masimo (MASI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Masimo (MASI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MASINegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Aphria (APHA) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Aphria's (APHA) fiscal first-quarter results are likely to reflect higher sales from medical and adult-use cannabis products.
SYKNegative Net Change DVANegative Net Change MASINegative Net Change APHANegative Net Change
earnings medical
Why Masimo (MASI) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
MASINegative Net Change
earnings earnings-beat earnings-esp earnings-estimates earnings-streak zacks-consensus-estimate
What's in Store for Intuitive Surgical's (ISRG) Q3 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) third-quarter earnings are likely to reflect weaker-than-expected performance at Instruments & Accessories segment.
SYKNegative Net Change ISRGNegative Net Change MASINegative Net Change TMONegative Net Change
earnings medical
3 Large-Cap MedTech Growth Stocks to Buy Amid the Pandemic
by Sriparna Ghosal
Let's take a look at three large-cap MedTech stocks that are currently flourishing on the back of a number of positive developments.
MASINegative Net Change RMDNegative Net Change ABTNegative Net Change TMONegative Net Change LHCGNegative Net Change NVCRNegative Net Change
medical